ERBB2 and breast cancer: Although up to 16% of patients with breast cancer will develop brain metastases, particular molecular subtypes like human epidermal growth factor receptor 2 (HER2) positive and triple-negative breast cancer (TNCB) will have a greater predisposition for this event [4,5].